Brokerages Set Arsanis Inc (ASNS) Target Price at $14.25

Shares of Arsanis Inc (NASDAQ:ASNS) have been assigned an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $14.25.

Several brokerages recently weighed in on ASNS. ValuEngine downgraded Arsanis from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Zacks Investment Research downgraded Arsanis from a “buy” rating to a “hold” rating in a report on Monday, October 15th.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of Arsanis by 27.1% during the second quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock worth $812,000 after purchasing an additional 47,777 shares during the period. Alambic Investment Management L.P. lifted its holdings in shares of Arsanis by 1,004.6% during the third quarter. Alambic Investment Management L.P. now owns 133,661 shares of the company’s stock worth $217,000 after purchasing an additional 121,561 shares during the period. Finally, Granahan Investment Management Inc. MA acquired a new stake in shares of Arsanis during the second quarter worth $365,000. 64.25% of the stock is owned by hedge funds and other institutional investors.

Shares of ASNS traded down $0.19 during mid-day trading on Wednesday, reaching $3.51. 157,453 shares of the company’s stock were exchanged, compared to its average volume of 550,800. The company has a current ratio of 5.08, a quick ratio of 5.08 and a debt-to-equity ratio of 0.28. The firm has a market cap of $49.10 million, a PE ratio of -0.22 and a beta of 1.78. Arsanis has a 52-week low of $1.15 and a 52-week high of $28.69.

Arsanis (NASDAQ:ASNS) last announced its earnings results on Friday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Arsanis Company Profile

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Featured Story: How does a reverse stock split work?

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply